Product Data Sheet

Product Name: LL-K8-22
Cat. No.: GC73219

Chemical Properties

Cas. No.			
Formula	$C_{37}H_{43}N_5O$	M.Wt	573.77
Solubility	DMSO : 125 mg/mL (217.86 mM; Need ultrasonic)	Storage	-20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			



Background

LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μM, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research.

LL-K8-22 (0-10 μM, 24 h) degrades the CDK8-cyclin C complex in a dose-dependent manner[1]. LL-K8-22 (0-20 μM, 4 days) suppresses tumor cell proliferation[1].LL-K8-22 (0-8 μM, 24 h) inhibits

Product Data Sheet

CDK8-cyclin C downstream signaling[1]. LL-K8-22 significantly downregulated EAPP (E2F family binding protein)[1].LL-K8-22 dose not affect CDK8 and CCNC mRNA levels[1].

References:

[1]. Wang M, et al. Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex. J Med Chem. 2023 Apr 13;66(7):4932-4951.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA